Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 16/20 | 0.50 |
| ▸ | BRD2 | P25440 | 16/20 | 0.50 |
| ▸ | BRD3 | Q15059 | 15/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20270176 | 0.86 | BRD4 (0.66) | BRD4BRD2BRD3CYP3A4CYP2D6 | |
| SCHEMBL20288807 | 0.86 | BRD4 (0.66) | BRD4BRD2BRD3CYP3A4CYP2D6 | |
| SCHEMBL23467420 | 0.85 | BRD4 (0.54) | BRD4BRD2BRD3GRIA2KCNH2 | |
| SCHEMBL20270105 | 0.85 | BRD4 (0.65) | BRD4BRD2BRD3CYP3A4CYP2D6 | |
| SCHEMBL20288809 | 0.85 | BRD4 (0.65) | BRD4BRD2BRD3CYP3A4CYP2D6 | |
| SCHEMBL23467447 | 0.83 | BRD4 (0.65) | BRD4BRD2BRD3CYP3A4CYP2D6 | |
| SCHEMBL23467444 | 0.82 | BRD4 (0.64) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL23467402 | 0.81 | BRD4 (0.59) | BRD4BRD2BRD3 | |
| SCHEMBL23467469 | 0.80 | BRD4 (0.61) | BRD4BRD2BRD3CYP3A4CYP2D6 | |
| SCHEMBL23569933 | 0.80 | BRD4 (0.57) | BRD4BRD2BRD3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028051-B2 | Tetrahydroquinoline-based bromodomain inhibitors | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2021-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11028051-B2 | Tetrahydroquinoline-based bromodomain inhibitors | BRDT, BRD4, BRD3 | BRD4 2/4885BRD2 4/4885BRD3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.